Sedana Medical AB (SEDANA) AI Stock Analysis

• Market Cap: kr983.44M
• Dividend Yield: N/A
• Average Volume (3M): 247.68K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: 13.48%
• EPS Growth: 28.98%
• Country: SE
• Employees: 113
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.12
• Shares Outstanding: 99,336,960
• 10 Day Avg. Volume: 186,290
• 30 Day Avg. Volume: 247,675
• PEG Ratio: 2.17
• Price to Book (P/B): 1.98
• Price to Sales (P/S): 10.60
• P/FCF Ratio: -10.15
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: kr10.00 ▼(-6.72% Downside)

Sedana Medical AB's overall stock score reflects strong revenue growth but significant challenges in profitability and cash flow. Technical indicators suggest bearish momentum, and the valuation is unattractive due to negative earnings. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Revenue Growth

The company demonstrates a modest revenue growth rate of 4.64% in the TTM, indicating positive momentum and potential for market expansion.

Product Efficiency

Sedana's AnaConDa system allows for efficient administration of anesthetics, improving patient care and potentially increasing adoption in healthcare facilities.

Balance Sheet Stability

A low debt-to-equity ratio indicates minimal leverage and financial risk, providing a stable foundation for future growth and investment opportunities.

Negative Factors

Profitability Challenges

The company struggles with profitability, as shown by negative net profit margins (-25.93%) and EBIT margins (-20.65%), impacting long-term financial health.

Cash Flow Issues

Significant cash flow challenges, with negative operating cash flow, limit the company's ability to fund operations and invest in growth initiatives.

Return on Equity

A negative return on equity indicates challenges in generating shareholder returns, which may deter investment and affect long-term growth prospects.

Sedana Medical AB Business Overview & Revenue Model

Company Description

Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally. The company offers Sedaconda ACD-L and Sedaconda ACD-, which are disposable medical devices that enables the administration of volatile anesthetics; Sedaconda Syringe, a 50/60ml syringe; Sedaconda ACD starter kit; FlurAbsorb and FlurAbsorb-S, which are active carbon filters to capture waste anaesthetic gases from the exhaust of the ventilator; FlurAbsorb accessory kit comprising accessories to connect the exhaust of the ventilator and the gas monitor to the FlurAbsorb/FlurAbsorb-S; and FlurAbsorb mount to hold the filter during scavenging of anesthetic gas. It also provides AMG-06 Gas Monitor for continuous non-invasive sidestream monitoring of CO2 and anaesthetics concentration in inspired and expired gases; Sedaconda Filling Adapter, a single-use device for safe and easy extraction of isoflurane from a Sedaconda bottle to a Sedaconda Syringe; and various accessories comprising DRYLINE II Water Traps, WaterLock 2 water trap, Nafion Dryer Tubing, and Respiratory Gas Monitoring Line. Sedana Medical AB (publ) was founded in 1999 and is headquartered in Danderyd, Sweden.

How the Company Makes Money

Sedana Medical generates revenue through the sale of its medical devices, primarily the AnaConDa system, and related consumables. The company earns money from direct sales to hospitals and healthcare facilities, as well as through partnerships with distributors and medical supply companies. Key revenue streams include the initial sale of the AnaConDa device, ongoing sales of consumable products necessary for its operation, and potential licensing agreements for technology use. Additionally, Sedana Medical benefits from collaborations with healthcare institutions for clinical studies, which can also lead to increased product adoption and sales.

Sedana Medical AB Financial Statement Overview

Summary

Sedana Medical AB exhibits strong revenue growth but struggles with profitability and cash flow. The balance sheet is stable with low leverage, yet negative net profit and cash flow issues highlight the need for improved financial management.

Income Statement

Sedana Medical AB shows a strong gross profit margin of over 70% consistently, indicating efficient production. However, the company struggles with profitability, as evidenced by negative net profit and EBIT margins. Revenue growth is volatile, with a significant increase in the TTM period, but past years have shown fluctuations. Overall, while revenue is growing, the company is not yet profitable.

Balance Sheet

The balance sheet is relatively strong with a low debt-to-equity ratio, indicating low leverage and financial stability. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is high, suggesting a solid capital structure, but the company needs to improve profitability to enhance ROE.

Cash Flow

Cash flow analysis reveals challenges, with negative operating and free cash flows. The free cash flow to net income ratio is high, suggesting that cash flow issues are more severe than income statement losses. The company needs to improve cash generation to support operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	197.61M	178.75M	153.87M	122.86M	159.15M	141.77M
Gross Profit	139.25M	126.14M	108.98M	86.07M	106.71M	88.90M
EBITDA	-15.48M	-4.03M	-51.67M	-64.87M	-49.10M	-17.22M
Net Income	-40.65M	-10.67M	-59.61M	-73.51M	-57.97M	-27.14M
Balance Sheet
Total Assets	965.79M	1.02B	1.01B	1.08B	1.17B	600.10M
Cash, Cash Equivalents and Short-Term Investments	111.96M	193.96M	381.80M	607.74M	836.18M	376.17M
Total Debt	4.06M	5.92M	4.31M	8.74M	8.87M	8.29M
Total Liabilities	57.38M	61.17M	44.06M	52.43M	66.12M	49.00M
Stockholders Equity	908.41M	958.23M	970.00M	1.03B	1.10B	551.09M
Cash Flow
Free Cash Flow	-65.91M	-186.77M	-206.95M	-253.22M	-151.48M	-92.47M
Operating Cash Flow	-251.00K	-11.77M	-38.06M	-115.43M	-41.22M	-7.85M
Investing Cash Flow	-105.37M	-44.67M	-321.96M	-137.78M	-110.25M	-84.62M
Financing Cash Flow	-3.78M	-3.57M	-4.86M	-1.51M	605.07M	5.79M

Sedana Medical AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SEDANA, the sentiment is Negative. The current price of 10.72 is above the 20-day moving average (MA) of 10.26, above the 50-day MA of 10.10, and below the 200-day MA of 11.82, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 44.13 is Neutral, neither overbought nor oversold. The STOCH value of 19.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SEDANA.

Sedana Medical AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	66 Neutral	kr1.09B	46.67	6.93%	―	-5.80%	-65.99%
PAX	52 Neutral	kr1.27B	200.52	1.41%	―	21.71%	-80.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OSSD	50 Neutral	kr1.16B	-25.50	―	―	38.43%	57.76%
SEDANA	48 Neutral	kr983.44M	-24.19	-4.42%	―	13.48%	28.98%
INTEG.B	48 Neutral	kr275.75M	-7.39	-18.55%	―	0.62%	-82.70%
SEZI	43 Neutral	kr806.51M	-5.92	-36.55%	―	62.24%	21.16%

Sedana Medical AB Corporate Events

Sedana Medical CFO Johan Spetz to Depart After Driving Efficiency Gains

Sedana Medical AB announced that Chief Financial Officer Johan Spetz will leave the company to pursue a career opportunity outside the life science sector after serving in the role since March 2022. Spetz, credited by the CEO with playing a central role in the company’s transformation, improved performance, and achievements such as reaching EBITDA break-even in Europe and advancing preparations for a future US launch, will remain in post until a successor is appointed or until 19 June 2026 to ensure continuity, while the company has already started the recruitment process for a new CFO, signaling an orderly leadership transition with limited immediate disruption for operations and stakeholders.

The most recent analyst rating on (SE:SEDANA) stock is a Hold with a SEK10.00 price target. To see the full list of analyst forecasts on Sedana Medical AB stock, see the SE:SEDANA Stock Forecast page.

Sedana Medical Achieves Positive FDA Pre-NDA Meeting for Inhaled Sedation

Sedana Medical AB has successfully completed a pre-New Drug Application (NDA) meeting with the FDA, achieving broad alignment on the contents of its NDA for inhaled sedation in mechanically ventilated adult patients. The FDA confirmed that the safety and efficacy data from Sedana’s clinical trials are adequate for submission, with additional analyses required for run-in training patients. The NDA submission is anticipated around mid-2026, marking a significant step towards entering the high-potential market for inhaled sedation.

The most recent analyst rating on (SE:SEDANA) stock is a Hold with a SEK9.00 price target. To see the full list of analyst forecasts on Sedana Medical AB stock, see the SE:SEDANA Stock Forecast page.

Sedana Medical Reports Improved Q3 Performance Amid Market Challenges

Sedana Medical AB reported a 4% increase in net sales for Q3 2025 compared to the same period in 2024, with a notable improvement in EBITDA performance despite market challenges. The company experienced improved cash flow from operations and a reduction in operating costs, although cash flow from investments remained negative due to ongoing registration preparation work in the USA. The financial results reflect Sedana Medical’s strategic focus on enhancing operational efficiency and expanding its market presence in the medtech and pharmaceutical sectors.

The most recent analyst rating on (SE:SEDANA) stock is a Hold with a SEK12.00 price target. To see the full list of analyst forecasts on Sedana Medical AB stock, see the SE:SEDANA Stock Forecast page.

Sedana Medical Announces 2026 Nomination Committee Formation

Sedana Medical AB has announced the formation of its Nomination Committee for the 2026 Annual General Meeting, comprising members appointed by its three largest shareholders and the Chairman of the Board. This committee, representing 31.69% of the voting rights, will propose resolutions for the meeting, including board composition and auditor appointments, impacting the company’s governance and strategic direction.

The most recent analyst rating on (SE:SEDANA) stock is a Hold with a SEK14.00 price target. To see the full list of analyst forecasts on Sedana Medical AB stock, see the SE:SEDANA Stock Forecast page.

Sedana Medical to Present Q3 2025 Interim Report

Sedana Medical AB is set to release its interim report for the third quarter of 2025 on October 24, with a presentation scheduled later that day. The company’s CEO, CFO, and CMO will present the report and address questions, highlighting its ongoing commitment to transparency and stakeholder engagement.

The most recent analyst rating on (SE:SEDANA) stock is a Hold with a SEK14.00 price target. To see the full list of analyst forecasts on Sedana Medical AB stock, see the SE:SEDANA Stock Forecast page.